Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8953439 | 1.00 | KDM6B (0.56) | KDM6BCPA1PPARGPPARAALDH1A1 | |
| SCHEMBL2769600 | 1.00 | KDM6B (0.56) | KDM6BCPA1PPARGPPARAALDH1A1 | |
| SCHEMBL1906640 | 1.00 | KDM6B (0.56) | KDM6BCPA1PPARGPPARAALDH1A1 | |
| SCHEMBL18248073 | 0.94 | KDM6B (0.51) | KDM6BCPA1PPARGPPARAALDH1A1 | |
| SCHEMBL28815028 | 0.94 | KDM6B (0.51) | KDM6BCPA1PPARGPPARAALDH1A1 | |
| SCHEMBL10891346 | 0.89 | KDM6B (0.67) | KDM6BACEMME | |
| SCHEMBL754625 | 0.83 | LDHA (0.57) | CPA1PPARGPPARAALDH1A1TRPA1 | |
| SCHEMBL1907744 | 0.82 | EPHX1 (0.45) | CPA1PPARGPPARATRPA1 | |
| SCHEMBL5807390 | 0.82 | TRPA1 (0.48) | KDM6BCPA1PPARGPPARATRPA1 | |
| SCHEMBL235131 | 0.81 | KDM6B (0.63) | KDM6BACEMMECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497636-B2 | Recombinant Saccharomyces cerevisiae cells for cannabinoid production | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-12-16 | — | — | US | claimed |
| EP-1639119-B1 | METHOD FOR THE MICROBIOLOGICAL ISOMERISATION OF ALPHA-HYDROXY CARBOXYLIC ACIDS | BASF SE (DE) | 2010-04-21 | — | — | EP | claimed |
| EP-1639119-A1 | METHOD FOR THE MICROBIOLOGICAL ISOMERISATION OF ALPHA-HYDROXY CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004111257-A1 | METHOD FOR THE MICROBIOLOGICAL ISOMERISATION OF ALPHA-HYDROXY CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | WO | claimed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023196307-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-114891070-A | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-107835818-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| CN-110167921-A | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | 勃林格殷格翰动物保健美国公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | disclosed |
| EP-0634408-B1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1073672-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057135-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| CN-1039331-C | Depsispeptide derivative, preparation and application of same | FUJISAMA PHARMACEUTICAL CO LTD (JP) | 1998-07-29 | — | — | CN | disclosed |
| US-5679671-A | ANGIOTENSIN 1-CONVERTING ENZYME INHIBITOR, VASOPRESSIN ANTAGONISM AND ATRIAL NAUTRIURETIC PEPTIDE HYDROLASE INHIBITOR | EISAI CO., LTD. (JP) | 1997-10-21 | — | — | US | disclosed |
| EP-0671172-A1 | AMINO ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0634408-A1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
| CN-1080932-A | Depsipeptide derivative and manufacture method thereof and purposes | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | KDM6B 4705/4885CPA1 334/4885PPARG 2686/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | KDM6B 2032/4885CPA1 46/4885PPARG 3652/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | KDM6B 1931/4885CPA1 35/4885PPARG 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.